Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.

Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Zhang J, Sepesi B, Vaporciyan AA, Swisher SG, Heymach JV, Zhang J, Gomez DR, Antonoff MB.

Clin Lung Cancer. 2019 Aug 1. pii: S1525-7304(19)30211-6. doi: 10.1016/j.cllc.2019.07.007. [Epub ahead of print]

PMID:
31447303
2.

Postoperative Urinary Tract Infection Quality Assessment and Improvement: The S.T.O.P. UTI Program and Its Impact on Hospitalwide CAUTI Rates.

Narula N, Lillemoe HA, Caudle AS, Chemaly RF, Anderson JJ, Segal C, Porter CA, Swisher SG, Levenback CF, Aloia TA.

Jt Comm J Qual Patient Saf. 2019 Jul 29. pii: S1553-7250(19)30298-3. doi: 10.1016/j.jcjq.2019.06.001. [Epub ahead of print]

PMID:
31371099
3.

Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience.

Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL.

Dis Esophagus. 2019 Jul 17. pii: doz067. doi: 10.1093/dote/doz067. [Epub ahead of print]

PMID:
31313820
4.

Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy.

Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris VK, Antonoff MB.

J Surg Oncol. 2019 Sep;120(4):729-735. doi: 10.1002/jso.25630. Epub 2019 Jul 9.

PMID:
31290159
5.

Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.

Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B.

Cancer. 2019 Jul 9. doi: 10.1002/cncr.32366. [Epub ahead of print]

PMID:
31287557
6.

Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization.

Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B.

Am J Cancer Res. 2019 Jun 1;9(6):1201-1211. eCollection 2019.

7.

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.

Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J.

Nat Commun. 2019 Jul 5;10(1):2978. doi: 10.1038/s41467-019-10877-8.

8.

Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.

Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003383. [Epub ahead of print]

PMID:
31188215
9.

Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B.

J Thorac Dis. 2019 Apr;11(4):1269-1278. doi: 10.21037/jtd.2019.04.27.

10.

Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.

Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL.

Ann Thorac Surg. 2019 Sep;108(3):845-851. doi: 10.1016/j.athoracsur.2019.04.024. Epub 2019 May 15.

PMID:
31102632
11.

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV.

J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.

PMID:
31067138
12.

Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience.

Nelson DB, Mehran RJ, Mitchell KG, Rajaram R, Correa AM, Bassett RL Jr, Antonoff MB, Hofstetter WL, Roth JA, Sepesi B, Swisher SG, Walsh GL, Vaporciyan AA, Rice DC.

Ann Thorac Surg. 2019 Aug;108(2):370-376. doi: 10.1016/j.athoracsur.2019.03.051. Epub 2019 Apr 18.

PMID:
31004583
13.

Facilitation of Surgical Innovation: Is It Possible to Speed the Introduction of New Technology While Simultaneously Improving Patient Safety?

Marcus RK, Lillemoe HA, Caudle AS, Weinberg JS, Gidley PW, Skibber JM, Levenback CF, Swisher SG, Aloia TA.

Ann Surg. 2019 Mar 26. doi: 10.1097/SLA.0000000000003290. [Epub ahead of print]

PMID:
30946086
14.

Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):742-750. doi: 10.1164/rccm.201806-1178OC.

PMID:
30896962
15.

Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?

Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL.

Dis Esophagus. 2019 Mar 19. pii: doz016. doi: 10.1093/dote/doz016. [Epub ahead of print]

PMID:
30888418
16.

Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.

Ning MS, Gomez DR, Heymach JV, Swisher SG.

Transl Lung Cancer Res. 2019 Feb;8(1):97-106. doi: 10.21037/tlcr.2018.09.21. Review.

17.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR Jr, Lee JJ, Heymach JV, Zhang J.

J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.

PMID:
30780001
18.

Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.

Kim MP, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.

J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.

19.

Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases.

Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Rice DC, Vauthey JN, Mehran RJ.

J Thorac Cardiovasc Surg. 2019 Apr;157(4):1648-1655. doi: 10.1016/j.jtcvs.2018.10.156. Epub 2018 Nov 26.

PMID:
30635188
20.

Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing.

Van Haren RM, Correa AM, Sepesi B, Rice DC, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Roth JA, Swisher SG, Antonoff MB.

Ann Thorac Surg. 2019 Mar;107(3):936-940. doi: 10.1016/j.athoracsur.2018.09.016. Epub 2018 Oct 26.

PMID:
30612991
21.

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.

Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B.

J Transl Med. 2018 Nov 26;16(1):328. doi: 10.1186/s12967-018-1704-3.

22.

Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.

Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng QH, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B.

Cancer Res. 2019 Jan 1;79(1):125-132. doi: 10.1158/0008-5472.CAN-18-1938. Epub 2018 Nov 6.

PMID:
30401714
23.

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV.

Clin Lung Cancer. 2019 Jan;20(1):43-47. doi: 10.1016/j.cllc.2018.09.015. Epub 2018 Sep 24.

PMID:
30343004
24.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II.

Clin Cancer Res. 2019 Jan 1;25(1):150-157. doi: 10.1158/1078-0432.CCR-17-2543. Epub 2018 Oct 4.

PMID:
30287547
25.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

PMID:
30228210
26.

Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.

Spicer JD, Shewale JB, Nelson DB, Mitchell KG, Bott MJ, Vallières E, Wilshire CL, Vaporciyan AA, Swisher SG, Jones DR, Darling GE, Sepesi B.

Ann Thorac Surg. 2019 Jan;107(1):277-284. doi: 10.1016/j.athoracsur.2018.07.033. Epub 2018 Sep 15.

PMID:
30227129
27.

Oesophageal preservation in locally advanced oesophageal cancer.

Ajani JA, Bhutani MS, Swisher SG.

Lancet Oncol. 2018 Sep;19(9):e430. doi: 10.1016/S1470-2045(18)30617-X. No abstract available.

PMID:
30191840
28.

Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women.

Nelson DB, Lapid DJ, Mitchell KG, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Nov;106(5):1499-1503. doi: 10.1016/j.athoracsur.2018.06.070. Epub 2018 Aug 15.

PMID:
30118712
29.

Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series.

Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B.

J Surg Oncol. 2018 Sep;118(3):518-524. doi: 10.1002/jso.25162. Epub 2018 Aug 15.

PMID:
30109699
30.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN Jr, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II.

J Immunother Cancer. 2018 Jun 6;6(1):48. doi: 10.1186/s40425-018-0368-0.

31.

Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2018;94(6):345-353. doi: 10.1159/000486720. Epub 2018 Apr 27.

32.

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG.

Cancer Med. 2018 Jun;7(6):2405-2414. doi: 10.1002/cam4.1505. Epub 2018 Apr 19.

33.

Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients.

Sepesi B, Ye Y, Mitchell KG, Zhang L, Gu J, Ji L, Antonoff MB, Hofstetter WL, Rice DC, Mehran RJ, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Wu X.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2635-2645.e15. doi: 10.1016/j.jtcvs.2018.02.015. Epub 2018 Feb 15.

PMID:
29548588
34.

Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components.

Nelson DB, Godoy MCB, Benveniste MF, Shewale JB, Spicer JD, Mitchell KG, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jul;106(1):235-241. doi: 10.1016/j.athoracsur.2018.02.020. Epub 2018 Mar 11.

PMID:
29534957
35.

Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer.

Van Haren RM, Mehran RJ, Mena GE, Correa AM, Antonoff MB, Baker CM, Woodard TC, Hofstetter WL, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC.

Ann Thorac Surg. 2018 Jul;106(1):272-279. doi: 10.1016/j.athoracsur.2018.01.088. Epub 2018 Mar 9.

PMID:
29530770
36.

Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.

Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J.

Ann Thorac Surg. 2018 Jun;105(6):1621-1626. doi: 10.1016/j.athoracsur.2018.01.081. Epub 2018 Mar 3.

PMID:
29510096
37.

Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer.

Shewale JB, Nelson DB, Rice DC, Sepesi B, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jun;105(6):1671-1677. doi: 10.1016/j.athoracsur.2018.01.031. Epub 2018 Feb 9.

PMID:
29432718
38.

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J.

Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. Epub 2018 Feb 6.

39.

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B.

Oncoimmunology. 2017 Oct 31;7(1):e1376156. doi: 10.1080/2162402X.2017.1376156. eCollection 2017.

40.

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R.

J Clin Oncol. 2018 Jun 20;36(18):1813-1822. doi: 10.1200/JCO.2017.74.0720. Epub 2018 Jan 2. Erratum in: J Clin Oncol. 2018 Aug 20;36(24):2570.

41.

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B.

Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.

42.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

43.

HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.

Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL.

Ann Thorac Surg. 2018 Feb;105(2):363-370. doi: 10.1016/j.athoracsur.2017.09.003. Epub 2017 Dec 7.

PMID:
29223420
44.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

45.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN Jr.

Ann Thorac Surg. 2018 Feb;105(2):418-424. doi: 10.1016/j.athoracsur.2017.08.052. Epub 2017 Dec 6.

46.

Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.

Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B.

Eur J Cardiothorac Surg. 2018 May 1;53(5):960-966. doi: 10.1093/ejcts/ezx427.

PMID:
29211849
47.

Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.

Wang JF, Pu X, Zhang X, Chen K, Xi Y, Wang J, Mao X, Zhang J, Heymach JV, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Meng QH, Shaw KR, Eterovic AK, Fang B.

Cancer. 2018 Mar 1;124(5):1061-1069. doi: 10.1002/cncr.31152. Epub 2017 Nov 27.

48.

Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study.

Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH.

Adv Radiat Oncol. 2017 Apr 19;2(3):316-324. doi: 10.1016/j.adro.2017.04.002. eCollection 2017 Jul-Sep.

49.

Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma.

Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA.

Oncotarget. 2017 May 23;8(45):79356-79365. doi: 10.18632/oncotarget.18119. eCollection 2017 Oct 3.

50.

RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.

Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH.

Clin Cancer Res. 2018 Jan 15;24(2):341-350. doi: 10.1158/1078-0432.CCR-17-1455. Epub 2017 Oct 13.

Supplemental Content

Loading ...
Support Center